Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (5,102) Arrow Down
Filter Results: (5,102) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (5,102)
    • People  (18)
    • News  (1,649)
    • Research  (2,742)
    • Events  (5)
    • Multimedia  (111)
  • Faculty Publications  (1,756)

Show Results For

  • All HBS Web  (5,102)
    • People  (18)
    • News  (1,649)
    • Research  (2,742)
    • Events  (5)
    • Multimedia  (111)
  • Faculty Publications  (1,756)
← Page 130 of 5,102 Results →
  • January 2001 (Revised October 2002)
  • Case

The American Medical Association-Sunbeam Deal (A): Serpent on the Staff Meets Chainsaw Al

By: Ashish Nanda and Kimberly A. Haddad
Facing dwindling membership and looking to increase its revenue, the American Medical Association (AMA) signed an endorsement deal with Sunbeam Corp., a leader in the small home appliance industry, in August 1997. In the deal, the AMA would receive significant... View Details
Keywords: Conflict of Interests; Organizations; Health Care and Treatment; Health Industry; United States
Citation
Find at Harvard
Related
Nanda, Ashish, and Kimberly A. Haddad. "The American Medical Association-Sunbeam Deal (A): Serpent on the Staff Meets Chainsaw Al." Harvard Business School Case 801-326, January 2001. (Revised October 2002.)
  • January 2001 (Revised July 2003)
  • Case

Pharmacyclics: Financing Research & Development

By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Health Industry; Health Industry; Health Industry
Citation
Educators
Purchase
Related
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
  • Web

2023 Reunion Presentations - Alumni

relaxing the ownership role of physicians in such sites. Some health insurers added technology as a major asset, and VCs and PEs invested heavily in these innovative... View Details
  • Web

Contact Us

our office to learn more about our students and alumni or to develop a customized recruiting strategy. Name* Contact Email* Subject* Employer Name Select Industry Consulting Consumer Products Energy / Utilities Entertainment / Media Government View Details
  • February 2024
  • Article

An Economic Framework for Vaccine Prioritization

By: Mohammad Akbarpour, Eric Budish, Piotr Dworczak and Scott Duke Kominers
We propose an economic framework for determining the optimal allocation of a scarce supply of vaccines that become gradually available during a public health crisis, such as the Covid-19 pandemic. Agents differ in observable and unobservable characteristics, and the... View Details
Keywords: Vaccine; Fairness; Public Finance; Public Goods; Allocation Problems; Allocative Efficiency; Allocation Rules; Social Welfare; Pandemics; Inequality; COVID-19; COVID-19 Pandemic; Public Sector; Resource Allocation; Market Design; Marketplace Matching; Public Administration Industry
Citation
SSRN
Read Now
Related
Akbarpour, Mohammad, Eric Budish, Piotr Dworczak, and Scott Duke Kominers. "An Economic Framework for Vaccine Prioritization." Quarterly Journal of Economics 139, no. 1 (February 2024): 359–417. (Authors' names are in certified random order.)
  • 01 Oct 2001
  • Research & Ideas

How To Make Restructuring Work for Your Company

8 The Devil Is In The Details The decisions that managers have to make as part of implementing a restructuring plan are often critical to whether the restructuring succeeds or fails. In the language of... View Details
Keywords: by Stuart C. Gilson
  • 22 Feb 2024
  • Research & Ideas

How to Make AI 'Forget' All the Private Data It Shouldn't Have

They already offer fine tuning and customization of models through their application programming interfaces. This will also help facilitate more high-risk use cases in areas like health View Details
Keywords: by Rachel Layne; Technology; Information Technology
  • 02 Jun 2020
  • Research & Ideas

Coronavirus Careers: Cloud Kitchens Are Now Serving

to the ease of online delivery using sophisticated apps. A very large number of people have also become aware of the health risks of eating in packed restaurants. Even in the... View Details
Keywords: by Lena Ye and Geoffrey Jones; Food & Beverage
  • 07 Feb 2023
  • Research & Ideas

Supervisor of Sandwiches? More Companies Inflate Titles to Avoid Extra Pay

see it happening at the Gap and Pizza Hut, but we also see it happening at Facebook, JPMorgan, and health care firms.” There are now hundreds of thousands of workers across the US with dubious managerial... View Details
Keywords: by Scott Van Voorhis
  • 17 Aug 2020
  • Research & Ideas

What the Stockdale Paradox Tells Us About Crisis Leadership

even excluding COVID-19 deaths) Mental health crises Secondary health problems from neglect/postponement of routine/preventative care Mass unemployment Dining, entertainment,... View Details
Keywords: by Boris Groysberg and Robin Abrahams
  • February 2019 (Revised September 2019)
  • Case

Theranos: The Unicorn That Wasn't

By: Joseph B. Fuller and John Masko
In 2003, 19-year-old Elizabeth Holmes founded a startup dedicated to making blood testing easier and more affordable. By 2015, her company, Theranos, was worth $9 billion. It boasted a star-studded board and contracts with national pharmacy and supermarket chains... View Details
Keywords: Theranos; Blood; Lab Testing; Fraud; Holmes; Balwani; Shultz; Carreyrou; Securities And Exchange Commission; Food And Drug Administration; FDA; SEC; Health Testing and Trials; Corporate Accountability; Organizational Culture; Misleading and Fraudulent Advertising; Crime and Corruption; Entrepreneurship; Medical Devices and Supplies Industry
Citation
Educators
Purchase
Related
Fuller, Joseph B., and John Masko. "Theranos: The Unicorn That Wasn't." Harvard Business School Case 319-068, February 2019. (Revised September 2019.)
  • 06 Oct 2008
  • Research & Ideas

Updating a Classic: Writing a Great Business Plan

about access to capital. Many great ventures in the Internet era (pre-1999) ended up failing because they assumed they would have continued access to cheap capital. Many of those businesses failed, though the underlying idea was sensible.... View Details
Keywords: by Sean Silverthorne
  • Web

Organizational Behavior - Faculty & Research

challenging Hillen to ensure the AI factory could continuously refine the technology to improve decision-making in dental practices. Keywords: Diagnostics ; Organization Design ; Change Management ; Disruption ; Transformation ; View Details

    Political Standards

    The University of Chicago Press November 2015.

    Prudent, verifiable, and timely corporate accounting is a bedrock of our modern capitalist system. In recent years, however, the rules that govern corporate accounting have been subtly changed in... View Details

    • 06 May 2014
    • First Look

    First Look: May 6

    Purchase this case: http://hbr.org/product/glaxosmithkline-in-china-a/an/514049-PDF-ENG Harvard Business School Case 514-050 GlaxoSmithKline in China (B) In 2013, Chinese investigators detained four... View Details
    Keywords: Sean Silverthorne
    • January 2002
    • Case

    Price-Fixing Vignettes

    By: Guhan Subramanian and Michelle Kalka
    This case escribes the antitrust prosecutions in the United States and abroad of the international bulk vitamins cartel. Both the civil and criminal fines were historically high, and it was the first time the United States prosecuted foreign nationals for U.S. criminal... View Details
    Keywords: Price; Lawsuits and Litigation; Governance Compliance; Auctions; Laws and Statutes; Monopoly; Globalized Markets and Industries; Health Industry; Health Industry; United States
    Citation
    Educators
    Purchase
    Related
    Subramanian, Guhan, and Michelle Kalka. "Price-Fixing Vignettes." Harvard Business School Case 902-068, January 2002.
    • June 2013
    • Case

    Ron Ventura at Mitchell Memorial Hospital

    By: Frank V. Cespedes and Heide Abelli
    Mitchell Memorial Hospital is a 750-bed regional academic medical center in Ohio. Andy Prescott, Chief of the Cardiovascular Center, is reviewing the performance evaluations of his star vascular surgeon Ron Ventura. The evaluations, the result of a 360-degree... View Details
    Keywords: Performance Expectations; Conflict Management; Behavior; Groups and Teams; Organizational Culture; Resignation and Termination; Health Care and Treatment; Performance Evaluation; Health Industry; Ohio
    Citation
    Educators
    Purchase
    Related
    Cespedes, Frank V., and Heide Abelli. "Ron Ventura at Mitchell Memorial Hospital." Harvard Business School Brief Case 913-572, June 2013.
    • Web

    Finance - Faculty & Research

    end of 2024. Keywords: Corporate Strategy ; Finance ; Transformation ; Leading Change ; Health Industry ; United States ; Germany Citation Purchase Related Collis, David J., Benjamin C. Esty, and Haisley Wert. "#FutureFresenius:... View Details
    • Web

    Faculty & Research - Global

    with Kansas City and Ford to expand Bridj's reach to the midwest. May 2025 Case Humana Commits to Value-Based Care By: V.G. Narayanan , Henry Eyring and David Lane In late 2023, CEO Bruce Broussard reviewed... View Details
    • September 2021 (Revised October 2022)
    • Supplement

    Hester Pharmaceuticals (B): Securing Supply

    By: Dante Roscini and John Masko
    Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details
    Keywords: COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Health Care and Treatment; Demand and Consumers; Global Range; Globalized Markets and Industries; Pharmaceutical Industry; Italy; China; United States; Germany
    Citation
    Purchase
    Related
    Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021. (Revised October 2022.)
    • ←
    • 130
    • 131
    • …
    • 255
    • 256
    • →
    ǁ
    Campus Map
    Harvard Business School
    Soldiers Field
    Boston, MA 02163
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College.